The Effectiveness of Silica Nanocomposites in the Treatment of Breast and Liver Cancer Through a Natural Physical Field
DOI:
https://doi.org/10.14738/jbemi.92.11851Keywords:
Silica nanocomposites; Cancer; Liver cancer; Breast cancer; Titanium dioxide.Abstract
Cancer survival rates, or survival statistics, show you the percentage of people who survive a specific type of cancer for a specific period of time. Cancer statistics use a five-year survival rate. Survival rates are usually given as percentages. For example, the five-year survival rate for breast or liver cancer is 77 percent. This means that, of all people diagnosed with breast or liver cancer, 77 out of 100 live to five years after being diagnosed with cancer. In contrast, 23 out of every 100 people die within five years of being diagnosed with breast or liver cancer. Despite the development of diagnostic and treatment methods, there is a significant meaning with chemotherapy, and a low cure rate. The current research aims to reveal the effectiveness of the impact of heat-treated silica nanoparticles with the addition of titanium dioxide on breast and liver cancer cells. The tests were carried out at the National Cancer Institute in the Arab Republic of Egypt, and the results showed a significant improvement in the rate of infection, as the percentage of tumors decreased by about 71%, which contributes significantly to the development of the patient's treatment condition.
References
Strongman, H., Gadd, S., Matthews, A., Mansfield, K. E., Stanway, S., Lyon, A. R., ... & Bhaskaran, K. (2019). Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. The Lancet, 394(10203), 1041-1054.
Atashzar, M. R., Baharlou, R., Karami, J., Abdollahi, H., Rezaei, R., Pourramezan, F., & Zoljalali Moghaddam, S. H. (2020). Cancer stem cells: A review from origin to therapeutic implications. Journal of cellular physiology, 235(2), 790-803.
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010). Targeting metabolic transformation for cancer therapy. Nature reviews cancer, 10(4), 267-277.
Hudecek, M.; Sommermeyer, D.; Kosasih, P.L.; Silva-Benedict, A.; Liu, L.; Rader, C.; Jensen, M.C.; Riddell, S.R. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 2015, 3, 125–135.
Watanabe, N.; Bajgain, P.; Sukumaran, S.; Ansari, S.; Heslop, H.E.; Rooney, C.M.; Brenner, M.K.; Leen, A.M.; Vera, J.F. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology 2016, 5, e1253656.
Crowther, M. D., & Sewell, A. K. (2021). The burgeoning role of MR1-restricted T-cells in infection, cancer and autoimmune disease. Current Opinion in Immunology, 69, 10-17.
Partridge, A. H., Burstein, H. J., & Winer, E. P. (2001). Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. JNCI Monographs, 2001(30), 135-142.
Nurgali, K., Jagoe, R. T., & Abalo, R. (2018). Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?. Frontiers in pharmacology, 9, 245.
Chin, V., Nagrial, A., Sjoquist, K., O'Connor, C. A., Chantrill, L., Biankin, A. V., ... & Yip, D. (2018). Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews, (3).
Morton, L. M., Dores, G. M., Schonfeld, S. J., Linet, M. S., Sigel, B. S., Lam, C. J., ... & Curtis, R. E. (2019). Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA oncology, 5(3), 318-325.
Turcotte, L. M., Neglia, J. P., Reulen, R. C., Ronckers, C. M., Van Leeuwen, F. E., Morton, L. M., ... & Henderson, T. O. (2018). Risk, risk factors, and surveillance of subsequent malignant neoplasms in survivors of childhood cancer: a review. Journal of Clinical Oncology, 36(21), 2145.
Grabher, B. J. (2020). Breast cancer: evaluating tumor estrogen receptor status with molecular imaging to increase response to therapy and improve patient outcomes. Journal of Nuclear Medicine Technology, 48(3), 191-201.
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., ... & Boyd, M. R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. JNCI: Journal of the National Cancer Institute, 82(13), 1107-1112.
Priem, B., van Leent, M. M., Teunissen, A. J., Sofias, A. M., Mourits, V. P., Willemsen, L., ... & Mulder, W. J. (2020). Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell, 183(3), 786-801.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Hesham Mohamed Abdal-Salam Yehia, Said Mahmoud Said
This work is licensed under a Creative Commons Attribution 4.0 International License.
